Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada

Jonathan Heppner, Leonard Tu Nguyen, Maggie Guo, Christopher Naugler, Fariborz Rashid-Kolvear, Jonathan Heppner, Leonard Tu Nguyen, Maggie Guo, Christopher Naugler, Fariborz Rashid-Kolvear

Abstract

Objective: The incidence of the combined myeloproliferative neoplasms (MPNs) was determined for a major Canadian city. Retrospective cases of MPN diagnoses (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) between 2011 to 2015 were retrieved from the Southern Alberta Cancer Cytogenetics Laboratory's database at Alberta Public Laboratories.

Results: An incidence rate of 2.05 cases per 100,000 person-years (95% CI 1.73-2.41) was determined, giving an age-standardized Canadian incidence of 2.71 cases per 100,000 person years (95% CI 2.63-2.78). MPN diagnoses occurred at a wide age range of 8-93 (median 66) and an age-dependent increase in incidence. Incidence rates for the MPNs are first reported here for a Canadian population.

Keywords: Cancer epidemiology; Essential thrombocythemia; Hematological neoplasm; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Age and sex-categorized incidence rates of myeloproliferative neoplasms in the Calgary metropolitan area (2011–2015)

References

    1. Swerdlow SHC, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4. Lyon: IARC Press; 2008.
    1. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97–105. doi: 10.1001/jamaoncol.2015.89.
    1. Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581–587. doi: 10.1002/ajh.23690.
    1. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol. 2015;141:2131–2138. doi: 10.1007/s00432-015-1983-5.
    1. Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017;98:85–93. doi: 10.1111/ejh.12788.
    1. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–297. doi: 10.1111/ejh.12256.
    1. Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Ann Hematol. 2017;96:373–381. doi: 10.1007/s00277-016-2902-9.
    1. Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada. BMC Res Notes. 2018;11:780. doi: 10.1186/s13104-018-3890-8.
    1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115:3842–3847. doi: 10.1002/cncr.24440.
    1. Boniol M, Heanue M. Age-standardisation and denominators. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, editors. Cancer incidence in five continents, IARC scientific publication no 160, vol IX. 2008/01/01 edition. France: International Agency for Research on Cancer, World Health Organization; 2008. pp. 9–101.
    1. Table 051-0056. Estimates of population by census metropolitan area, sex and age group for July 1, based on the Standard Geographical Classification (SGC) 2011, annual (persons). Ottawa. 2015. . Accessed 31 Jan 2017.
    1. Table 051-0001. Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). Ottawa. 2015. . Accessed 31 Jan 2017.
    1. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–212. doi: 10.1080/01621459.1927.10502953.
    1. Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474–1484. doi: 10.1002/ajh.25270.
    1. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413–437. doi: 10.1016/j.beha.2005.07.015.
    1. Swerdlow SHC, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4. Lyon: IARC Press; 2017.
    1. Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: comparison with the 2008 version. Am J Hematol. 2017;92:E48–E51. doi: 10.1002/ajh.24657.
    1. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680–692. doi: 10.1182/blood-2016-10-695957.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する